AstraZeneca Says Autoimmune Disease Treatment Ultomiris Met Phase 3 Trial Primary Endpoint
05 Mai 2022 - 8:52AM
Dow Jones News
By Michael Susin
AstraZeneca PLC said Thursday that its treatment for
neuromyelitis optica spectrum disorder (NMOSD) Ultomiris met the
primary endpoint in a Phase 3 clinical trial with a "statistically
significant and clinically meaningful" reduction in the risk of
relapse.
The Anglo-Swedish pharma giant said no relapse was observed in
58 patients during a treatment duration of 73 weeks.
"Every NMOSD relapse can have debilitating and irreversible
consequences, so reducing relapses is critical," lead primary
investigator in the trial Sean J. Pittock said.
The company said the data will be submitted to global health
authorities as rapidly as possible.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
May 05, 2022 02:37 ET (06:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
